Last reviewed 2026-04-20 · How we verify

Guaiastil (GUAIACOL)

Guaiastil, a marketed drug by an unspecified company, operates uniquely by inhibiting carbonic anhydrase 2 to reduce mucus production, primarily indicated for the common cold. Its key competitive advantage lies in its distinct mechanism of action compared to off-patent drugs like acetazolamide and acetohydroxamic acid, which also target carbonic anhydrase but are widely available as generics. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.

At a glance

Approved indications

• Common cold
• Cough
• Nasal congestion
• Nasal discharge
• Rhinitis

Common side effects

No common side effects on file.

Key clinical trials

• Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction (NA)
• A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement (PHASE3)
• Evaluation of Pulpotomy Versus Pulpectomy in Primary Molars With Irreversible Pulpitis or Necrotic Pulp (NA)
• Intravenous Methocarbamol for Acute Pain After Spine Surgery
• Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure (NA)
• Methocarbamol in Ventral and Inguinal HR (PHASE4)
• Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures (PHASE4)
• A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Guaiastil CI brief — competitive landscape report
• Guaiastil updates RSS · CI watch RSS